Company News
 |
Company News |
Upcoming Events | Past Events | Email Alerts
Media Coverage: 2005-6 | 2003-4 | 2001-2 | 1998-2000
Media Coverage: 2005-6 | 2003-4 | 2001-2 | 1998-2000
Date: January 24, 2007
Title: Proneuron Announces the Receipt of a $430,000 Grant from the Michael J. Fox Foundation to Develop Its PN277 for the Treatment of Parkinson's Disease
Date: January 25, 2006
Title: Weizmann Institute scientists suggest that immune cells help to maintain cognition and brain cell renewal
Date: June 9, 2005
Title: CNN en español presentará un programa sobre ProCord, un tratamiento experimental para la lesión total de la médula espinal
Date: May 25, 2005
Title: ProCord Trial for Complete Spinal Cord Injury Now Live at Shepherd Center in Atlanta
Date: March 23, 2005
Title: Proneuron’s ProCord Granted European Patent
Date: February 15, 2005
Title: Proneuron Announces Milestone Patent for Copolymer-1 (Cop-1). Patent expands use of Cop-1, previously approved for the treatment of MS
Date: December 7, 2004
Title: Proneuron’s Phase II Experimental ProCord Procedure for Complete Spinal Cord Injury Now Available at The Mount Sinai Medical Center in NY & University Hospital in collaboration with Kessler Institute for Rehabilitation in NJ.
Date: September 13, 2004
Title: Proneuron’s ProCord Receives FDA Orphan Drug Designation
Date: September 7, 2004
Title: Proneuron Biotechnologies Welcomes Dr. Marca L. Sipski to the Company’s ProCord Study Steering Committee Guiding the Phase II Study of ProCord for Complete Spinal Cord Injury
Date: June 7, 2004
Title: Proneuron and Cell Design of Atlanta to Establish a New Cell Processing Facility in Atlanta to Support The Current Phase II Trial of ProCord for Complete Spinal Cord Injury
Date: June 6, 2004
Title: The Mount Sinai Medical Center and Kessler Institute for Rehabilitation Are Now Enrolling for Proneuron's Phase II Study of ProCord for Neurologically Complete Spinal Cord Injury - Announcement Made at the Rally for the Cure in NYC
Date: June 4, 2004
Title: AMERICAN-ISRAEL CHAMBER OF COMMERCE ANNOUNCES EAGLE STAR AWARDS Veritas Venture Partners and Proneuron Receive Company Awards
Date: March 9, 2004
Title: Shepherd Center and Proneuron Receive $3.2 Million Commitment From the Marcus Foundation for Phase II study of ProCord, an Experimental Procedure for Acute Spinal Cord Injury: Proneuron to Establish Cell Center in Atlanta to Support Shepherd’s Participation in this International, Multi-center, Randomized-controlled Trial
Date: January 8, 2004
Title: Proneuron’s ProCord Therapy for the Treatment of Acute Spinal Cord Injury featured in News Report on International Herald Tribune Television (IHT-TV)
ProCord package aired in 90 Countries Worldwide starting January 9-15, 2004
Date: December 8, 2003
Title: Proneuron Biotechnologies Teams with Craig Hospital in Denver to Expand IND Phase II Trial of ProCord for the Treatment of Spinal Cord Injuries to the U.S.
Date: October 27, 2003
Title: Proneuron Receives Award for Outstanding Contribution to the New Jersey-Israel Life Science Year in the Area of Spinal Cord and CNS Treatments at event Organized by the New Jersey-Israel Commission Award Presented by Gov. of NJ and Vice Prime Minister of Israel
Date: October 8, 2003
Title: Proneuron Biotechnologies Primes for U.S. Segment of IND Phase II study of ProCord for the Treatment of Acute Spinal Cord Injury.
Principal Investigators Meeting Held at the Kessler Institute for Rehabilitation in N.J.
Date: September 30, 2003
Title: Proneuron Biotechnologies Pre-Clinical Study Shows that Primed Macrophages Enhance Recovery of Function and Preserve the Integrity of a
Severely Injured Spinal Cord.
Date: September 23, 2003
Title: Proneuron Biotechnologies Announces a Phase II IND Study of Macrophage Therapy (ProCord) for the Treatment of Complete Spinal Cord Injury
Study investigators must be notified of a patient within a few days of injury
Date: September 22, 2003
Title: Proneuron Biotechnologies Inc. Announces Phase II Trial of Copolymer-1 for the Treatment of Patients with Huntington's Disease
Clinical Trial to Commence in Fall 2003
Date: June 25, 2003
Title: Progenitor Cell Therapy To Provide The Platform For Cell Processing For Proneuron's Clinical Trials with ProCord™ In New York and New Jersey
Date: June 25, 2003
Title: Proneuron Cell Processing Platform in Denver is Ready for the Clinical Trials with ProCord™
Date: February 18, 2003
Title: Dr. David Snyder appointed as VP Clinical Development of Proneuron Biotechnologies, Inc.
Date: August 13, 2002
Title: Proneuron announces FDA approval of further recruitment of patients with spinal cord injury for its experimental macrophage therapy following the completion of Phase 1 study
Date: August 5, 2002
Title: Jeremy Rome appointed as VP Finance of Proneuron Biotechnologies, Inc.
Date: June 25, 2002
Title: Proneuron Biotechnologies and Craig Hospital joint experimental program to treat Spinal Cord Injury receives US$ 1 million funding from the BIRD Foundation
Date: May 7, 2002
Title: Prof. Michal Schwartz of the Weizmann Institute of Science, scientific founder of Proneuron, wins Friedenwald Award at the ARVO Meeting.
Date: May 6, 2002
Title: Prof. Michal Schwartz of the Weizmann Institute of Science, Proneuron's scientific founder is chosen as the keynote speaker at the First Joint Conference of the American Spinal Injury Association and The International Medical Society of Paraplegia.
Date: April 10, 2002
Title: Proneuron completes patient recruitment for Its phase 1 clinical trial for complete spinal cord injury; patient enrollment continues for additional clinical trial.
Date: March 10, 2002
Title: Nir Nimrodi appointed as CEO of Proneuron Biotechnologies, Inc.
Date: December 4, 2001
Title: Proneuron Biotechnologies and Teva Pharmaceutical Industries sign agreement to develop Glatiramer Acetate for neurological diseases business editors and Health/Medical writers.
Date: October 22, 2001
Title: Proneuron Biotechnologies Announces Initiation of Second Phase 1 Clinical Trial in Complete Spinal Cord Injury.
Date: ---
Title: Eti Yoles, Ph.D., joins Proneuron Biotechnologies as VP Research.
Date: February 27, 2001
Title: The Early SHOW, CBS A transcript for the CBS interview.
Date: February 27, 2001
Title: Proneuron's first spinal cord injury patient interviewed on US national TV (The Early SHOW, CBS).
Date: August 9, 2000
Title: Proneuron is currently recruiting patients for a Phase 1 study on complete spinal cord injury.
Date: July 31, 2000
Title: Proneuron Biotechnologies announces initiation of phase 1 clinical trial in complete spinal cord injury.
Date: December 5, 1999
Title: Meeting of Scientific Advisory Board.
Date: November 24, 1999
Title: Prof. Edward Benzel and Prof. Siamon Gordon join Scientific Advisory Board.
Date: September 28, 1999
Title: FDA approves phase I clinical trial for Proneuron's spinal cord cell therapy.
Date: June 10, 1999
Title: Company expansion.
Date: June 4, 1999
Title: Application to U.S. Federal Authorities.
Date: May 9, 1999
Title: Clinical trials approved by local ethical review boards.
Date: March 11, 1999
Title: Changes to the Board of Directors.
Date: March 11, 1999
Title: New member in the Scientific Advisory Board.
Date: January 20, 1999
Title: New members in the Scientific Advisory Board.
Date: November 29, 1998
Title: Proneuron celebrates the opening of its new facilities.
Title: Proneuron Announces the Receipt of a $430,000 Grant from the Michael J. Fox Foundation to Develop Its PN277 for the Treatment of Parkinson's Disease
Date: January 25, 2006
Title: Weizmann Institute scientists suggest that immune cells help to maintain cognition and brain cell renewal
Date: September 12, 2005
Title: Phase I ProCord Study Results
Published in the Journal of Neurosurgery: Spine, September
2005 Issue.
Date: June 9, 2005
Title: CNN en español presentará un programa sobre ProCord, un tratamiento experimental para la lesión total de la médula espinal
Date: May 25, 2005
Title: ProCord Trial for Complete Spinal Cord Injury Now Live at Shepherd Center in Atlanta
Date: March 23, 2005
Title: Proneuron’s ProCord Granted European Patent
Date: February 15, 2005
Title: Proneuron Announces Milestone Patent for Copolymer-1 (Cop-1). Patent expands use of Cop-1, previously approved for the treatment of MS
Date: December 7, 2004
Title: Proneuron’s Phase II Experimental ProCord Procedure for Complete Spinal Cord Injury Now Available at The Mount Sinai Medical Center in NY & University Hospital in collaboration with Kessler Institute for Rehabilitation in NJ.
Date: November 18, 2004
Title: Shriners Hospitals for Children,
Philadelphia now enrolling for Proneuron’s Phase II Procord
Study
Date: November 16, 2004
Title: Rehabilitation Institute of Michigan
Is the First Midwest
Rehabilitation Hospital to Participate in Proneuron’s
Clinical Research Trial for Spinal Cord Injury
Date: September 13, 2004
Title: Proneuron’s ProCord Receives FDA Orphan Drug Designation
Date: September 7, 2004
Title: Proneuron Biotechnologies Welcomes Dr. Marca L. Sipski to the Company’s ProCord Study Steering Committee Guiding the Phase II Study of ProCord for Complete Spinal Cord Injury
Date: June 7, 2004
Title: Proneuron and Cell Design of Atlanta to Establish a New Cell Processing Facility in Atlanta to Support The Current Phase II Trial of ProCord for Complete Spinal Cord Injury
Date: June 6, 2004
Title: The Mount Sinai Medical Center and Kessler Institute for Rehabilitation Are Now Enrolling for Proneuron's Phase II Study of ProCord for Neurologically Complete Spinal Cord Injury - Announcement Made at the Rally for the Cure in NYC
Date: June 4, 2004
Title: AMERICAN-ISRAEL CHAMBER OF COMMERCE ANNOUNCES EAGLE STAR AWARDS Veritas Venture Partners and Proneuron Receive Company Awards
Date: March 9, 2004
Title: Shepherd Center and Proneuron Receive $3.2 Million Commitment From the Marcus Foundation for Phase II study of ProCord, an Experimental Procedure for Acute Spinal Cord Injury: Proneuron to Establish Cell Center in Atlanta to Support Shepherd’s Participation in this International, Multi-center, Randomized-controlled Trial
Date: January 8, 2004
Title: Proneuron’s ProCord Therapy for the Treatment of Acute Spinal Cord Injury featured in News Report on International Herald Tribune Television (IHT-TV)
ProCord package aired in 90 Countries Worldwide starting January 9-15, 2004
Date: December 8, 2003
Title: Proneuron Biotechnologies Teams with Craig Hospital in Denver to Expand IND Phase II Trial of ProCord for the Treatment of Spinal Cord Injuries to the U.S.
Date: October 27, 2003
Title: Proneuron Receives Award for Outstanding Contribution to the New Jersey-Israel Life Science Year in the Area of Spinal Cord and CNS Treatments at event Organized by the New Jersey-Israel Commission Award Presented by Gov. of NJ and Vice Prime Minister of Israel
Date: October 8, 2003
Title: Proneuron Biotechnologies Primes for U.S. Segment of IND Phase II study of ProCord for the Treatment of Acute Spinal Cord Injury.
Principal Investigators Meeting Held at the Kessler Institute for Rehabilitation in N.J.
Date: September 30, 2003
Title: Proneuron Biotechnologies Pre-Clinical Study Shows that Primed Macrophages Enhance Recovery of Function and Preserve the Integrity of a
Severely Injured Spinal Cord.
Date: September 23, 2003
Title: Proneuron Biotechnologies Announces a Phase II IND Study of Macrophage Therapy (ProCord) for the Treatment of Complete Spinal Cord Injury
Study investigators must be notified of a patient within a few days of injury
Date: September 22, 2003
Title: Proneuron Biotechnologies Inc. Announces Phase II Trial of Copolymer-1 for the Treatment of Patients with Huntington's Disease
Clinical Trial to Commence in Fall 2003
Date: June 25, 2003
Title: Progenitor Cell Therapy To Provide The Platform For Cell Processing For Proneuron's Clinical Trials with ProCord™ In New York and New Jersey
Date: June 25, 2003
Title: Proneuron Cell Processing Platform in Denver is Ready for the Clinical Trials with ProCord™
Date: February 18, 2003
Title: Dr. David Snyder appointed as VP Clinical Development of Proneuron Biotechnologies, Inc.
Date: August 13, 2002
Title: Proneuron announces FDA approval of further recruitment of patients with spinal cord injury for its experimental macrophage therapy following the completion of Phase 1 study
Date: August 5, 2002
Title: Jeremy Rome appointed as VP Finance of Proneuron Biotechnologies, Inc.
Date: June 25, 2002
Title: Proneuron Biotechnologies and Craig Hospital joint experimental program to treat Spinal Cord Injury receives US$ 1 million funding from the BIRD Foundation
Date: May 7, 2002
Title: Prof. Michal Schwartz of the Weizmann Institute of Science, scientific founder of Proneuron, wins Friedenwald Award at the ARVO Meeting.
Date: May 6, 2002
Title: Prof. Michal Schwartz of the Weizmann Institute of Science, Proneuron's scientific founder is chosen as the keynote speaker at the First Joint Conference of the American Spinal Injury Association and The International Medical Society of Paraplegia.
Date: April 10, 2002
Title: Proneuron completes patient recruitment for Its phase 1 clinical trial for complete spinal cord injury; patient enrollment continues for additional clinical trial.
Date: March 10, 2002
Title: Nir Nimrodi appointed as CEO of Proneuron Biotechnologies, Inc.
Date: December 4, 2001
Title: Proneuron Biotechnologies and Teva Pharmaceutical Industries sign agreement to develop Glatiramer Acetate for neurological diseases business editors and Health/Medical writers.
Date: October 22, 2001
Title: Proneuron Biotechnologies Announces Initiation of Second Phase 1 Clinical Trial in Complete Spinal Cord Injury.
Date: ---
Title: Eti Yoles, Ph.D., joins Proneuron Biotechnologies as VP Research.
Date: February 27, 2001
Title: The Early SHOW, CBS A transcript for the CBS interview.
Date: February 27, 2001
Title: Proneuron's first spinal cord injury patient interviewed on US national TV (The Early SHOW, CBS).
Date: August 9, 2000
Title: Proneuron is currently recruiting patients for a Phase 1 study on complete spinal cord injury.
Date: July 31, 2000
Title: Proneuron Biotechnologies announces initiation of phase 1 clinical trial in complete spinal cord injury.
Date: December 5, 1999
Title: Meeting of Scientific Advisory Board.
Date: November 24, 1999
Title: Prof. Edward Benzel and Prof. Siamon Gordon join Scientific Advisory Board.
Date: September 28, 1999
Title: FDA approves phase I clinical trial for Proneuron's spinal cord cell therapy.
Date: June 10, 1999
Title: Company expansion.
Date: June 4, 1999
Title: Application to U.S. Federal Authorities.
Date: May 9, 1999
Title: Clinical trials approved by local ethical review boards.
Date: March 11, 1999
Title: Changes to the Board of Directors.
Date: March 11, 1999
Title: New member in the Scientific Advisory Board.
Date: January 20, 1999
Title: New members in the Scientific Advisory Board.
Date: November 29, 1998
Title: Proneuron celebrates the opening of its new facilities.
Disclaimer | Site Map | Home Page| Contact Us
Proneuron Biotechnologies is engaged in research
related to spinal cord injuries and paralysis cure.
